Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Donepezil for psychotropic-induced memory loss.

F M Jacobsen1, L Comas-Díaz

  • 1Transcultural Mental Health Institute and the Department of Psychiatry and Behavioral Services, George Washington University School of Medicine, Washington, DC 20036-6043, USA.

The Journal of Clinical Psychiatry
|November 5, 1999
PubMed
Summary

Donepezil may improve memory loss, dry mouth, and constipation in adults with affective illness. However, it carries a risk of triggering mania in some patients, warranting careful monitoring.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Testicular torsion and subsequent testicular function in young men from the general population.

Human reproduction (Oxford, England)·2023
Same author

People of color as America's metaphor: on contact, rebirth, and evolution.

Cultural diversity & ethnic minority psychology·2004
Same author

Ethnocultural allodynia.

The Journal of psychotherapy practice and research·2001
Same author

Hispanics, Latinos, or Americanos: the evolution of identity.

Cultural diversity & ethnic minority psychology·2001
Same author

An ethnopolitical approach to working with people of color.

The American psychologist·2001
Same author

Ethnic minority psychology: identity, empowerment, and transformation.

Cultural diversity and mental health·1998

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Donepezil, an acetylcholinesterase inhibitor, is approved for Alzheimer's disease.
  • Its efficacy in non-geriatric affective illness is under investigation.
  • Focus on treating psychotropic-induced memory loss, dry mouth, and constipation.

Purpose of the Study:

  • To evaluate the effectiveness of donepezil in treating memory loss, dry mouth, and constipation in non-geriatric patients with affective illness.
  • To assess the tolerability and side effects of donepezil in this population.

Main Methods:

  • Open-label trials involving nondemented outpatients with stabilized affective illness.
  • Patients received donepezil, starting at 5 mg/day, then increasing to 10 mg/day.
  • Symptom ratings were collected using self-rating scales before and after dose adjustments.

Related Experiment Videos

Main Results:

  • Donepezil (5 mg/day) significantly improved memory loss (p<.001), dry mouth (p<.001), and constipation (p<.05).
  • A subset of patients showed further improvement at 10 mg/day (p = .057).
  • Adverse events included insomnia, nausea, vomiting, diarrhea, and notably, mania in two bipolar patients.

Conclusions:

  • Donepezil can alleviate memory loss, dry mouth, and constipation in non-geriatric patients with affective disorders.
  • A potential risk of inducing mania exists, particularly in bipolar patients.
  • Further research is needed to determine if donepezil's memory-restoring effects predict future Alzheimer's disease risk.